Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: Development of Diagnostic Tests and Kits for Detection of Pathological Angiogenesis in Cancer, 57832-57833 [2015-24331]
Download as PDF
<![CDATA[
57832
Federal Register / Vol. 80, No. 186 / Friday, September 25, 2015 / Notices
immunization information, smoking
cessation, oral health, as well as
parental depression, domestic violence
and substance use counseling.
Pediatricians would be asked about the
frequency with which they inquire
about, use formal screening instruments,
treat/manage, and refer patients for
various problems/conditions. These
various problems/conditions may
include maternal depression, parental
alcohol/drug use, divorce, illiteracy,
domestic violence exposure, physical or
sexual abuse, neglectful parenting, and
food and housing insecurity. Findings
from the AAP national survey of
pediatricians, in conjunction with
findings from other data sources and
ongoing surveys of home visitors, would
inform MCHB’s understanding of what
is needed to best strengthen the home
visitors’ and pediatricians’
collaborations for at-risk families to
support healthy development and to
Grantee/organization name
Grant number
The American Academy of Pediatrics .......................
U04MC07853 ............................................
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
[FR Doc. 2015–24395 Filed 9–24–15; 8:45 am]
Dated: September 21, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2015–24322 Filed 9–24–15; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
mstockstill on DSK4VPTVN1PROD with NOTICES
National Institute on Aging; Notice of
Closed Meeting
National Institutes of Health
Name of Committee: National Institute on
Aging Special Emphasis Panel; The Aging
and Memory Project.
Date: October 26, 2015.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, Suite 2C212, 7201
Wisconsin Avenue, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Kimberly Firth, Ph.D.,
National Institutes of Health, National
Institute on Aging, Gateway Building, 7201
Wisconsin Avenue, Suite 2C212, Bethesda,
MD 20892, 301–402–7702, firthkm@
mail.nih.gov.
VerDate Sep<11>2014
19:58 Sep 24, 2015
Jkt 235001
Prospective Grant of Start-Up
Exclusive Evaluation Option License
Agreement: Development of
Diagnostic Tests and Kits for Detection
of Pathological Angiogenesis in
Cancer
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of a
Start-Up Exclusive Evaluation Option
License Agreement to Angio360
Diagnostics, LLC, a company having a
place of business in Wauwatosa,
Wisconsin, to practice the inventions
embodied in U.S. Provisional Patent
Application No. 60/858,068, entitled
‘‘Differential Gene Expression in
Physiological and Pathological
Angiogenesis,’’ filed November 9, 2006
(HHS Ref. No.: E–285–2006/0–US–01);
US Provisional Patent Application No.
60/879,457, entitled ‘‘Organ And Tumor
Associated Endothelial Markers,’’ filed
January 8, 2007 (HHS Ref. No. E–285–
2006/1–US–01); PCT Application No.
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
FOR FURTHER INFORMATION CONTACT:
Lynn Van Pelt, DMD, Division of Child,
Adolescent, and Family Health,
Maternal and Child Health Bureau,
Health Resources and Services
Administration, 5600 Fishers Lane,
Room 18W13B, Rockville, Maryland
20857; lvanpelt@hrsa.gov.
State
Dated: September 21, 2015.
James Macrae,
Acting Administrator.
BILLING CODE 4165–15–P
address the toxic stress and social
determinants that drive health and
developmental disparities for young
children.
FY 2015
authorized
funding level
IL
$1,176,800
FY 2015
estimated
supplemental
funding
$75,000
PCT/US2007/072395, entitled
‘‘Differential Gene Expression in
Physiological and Pathological
Angiogenesis,’’ filed June 8, 2007 (HHS
Ref. No. E–285–2006/2–PCT–01); U.S.
Patent Application No. 12/514,297,
entitled ‘‘Differential Gene Expression
in Physiological and Pathological
Angiogenesis,’’ filed May 8, 2009 (HHS
Ref No. E–285–2006/2–US–02);
Australian Patent No. 2007–317753,
entitled ‘‘Differential Gene Expression
in Physiological and Pathological
Angiogenesis,’’ filed June 28, 2007 (HHS
Ref No. E–285–2006/2–AU–03);
Canadian Patent Application No.
2,669,260, entitled ‘‘Differential Gene
Expression in Physiological and
Pathological Angiogenesis,’’ filed June
28, 2007 (HHS Ref. No. E–285–2006/2–
CA–04); U.S. Patent No.: 8,440,411,
entitled ‘‘Differential Gene Expression
in Physiological and Pathological
Angiogenesis,’’ filed March 21, 2011
(HHS Ref. No. E–285–2006/2–US–05);
U.S. Patent Application No. 13/052,878,
entitled ‘‘Differential Gene Expression
in Physiological and Pathological
Angiogenesis,’’ filed April 16, 2013
(HHS Ref. No.: E–285–2006/2–US–06);
and Australian Application Patent No.:
2014–200453, entitled ‘‘Differential
Gene Expression in Physiological and
Pathological Angiogenesis,’’ filed
January 28, 2014 (HHS Ref No. E–285–
2006/2–AU–07). The patent rights in
these inventions have been assigned to
the Government of the United States of
America. The territory of the
prospective Start-Up Exclusive
Evaluation Option License Agreement
may be worldwide, and the field of use
may be limited to ‘‘Development of
diagnostic tests and kits to determine or
monitor pathological angiogenesis
related to cancer in animals or
humans.’’
E:\FR\FM\25SEN1.SGM
25SEN1
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 186 / Friday, September 25, 2015 / Notices
Upon the expiration or termination of
the Start-up Exclusive Evaluation
Option License Agreement, Angio360
Diagnostics, LLC will have the exclusive
right to execute a Start-Up Exclusive
Patent License Agreement which will
supersede and replace the Start-up
Exclusive Evaluation Option License
Agreement, with no greater field of use
and territory than granted in the Startup Exclusive Evaluation Option License
Agreement.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before
October 13, 2015 will be considered.
ADDRESSES: Requests for copies of the
patent application(s), inquiries,
comments, and other materials relating
to the contemplated Start-Up Exclusive
Evaluation Option License Agreement
should be directed to: Rose M. Freel,
Licensing and Patenting Manager, Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 402–
9521; Facsimile: (301) 402–0220; Email:
rose.freel@nih.gov. A signed
confidentiality nondisclosure agreement
will be required to receive copies of any
patent applications that have not been
published or issued by the United States
Patent and Trademark Office or the
World Intellectual Property
Organization.
SUPPLEMENTARY INFORMATION: This
technology describes a method of
detecting pathological angiogenesis
(formation of new blood vessels) using
the expression levels of certain proteins
for the diagnosis of cancer or monitoring
response to cancer treatment.
The prospective Start-Up Exclusive
Evaluation Option License Agreement is
being considered under the small
business initiative launched on October
1, 2011 and will comply with the terms
and conditions of 35 U.S.C. 209 and 37
CFR part 404. The prospective Start-Up
Exclusive Evaluation Option License
Agreement and a subsequent Start-Up
Exclusive Patent License Agreement
may be granted unless the NIH receives
written evidence and argument, within
fifteen (15) days from the date of this
published notice, that establishes that
the grant of the contemplated Start-Up
Exclusive Evaluation Option License
Agreement would not be consistent with
the requirements of 35 U.S.C. 209 and
37 CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Start-Up Exclusive
VerDate Sep<11>2014
19:58 Sep 24, 2015
Jkt 235001
Evaluation Option License Agreement.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: September 21, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology
Transfer, National Institutes of Health.
[FR Doc. 2015–24331 Filed 9–24–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Cell Biology.
Date: October 14, 2015.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: John Burch, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institute of
Health, 6701 Rockledge Drive, Room 3213,
MSC 7808, Bethesda, MD 20892, 301–408–
9519, burchjb@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Oncology 2—
Translational Clinical Integrated Review
Group; Clinical Oncology Study Section.
Date: October 19, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Sheraton Reston Hotel, 11810
Sunrise Valley Drive, Reston, VA 20191.
Contact Person: Malaya Chatterjee, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
57833
Health, 6701 Rockledge Drive, Room 6192,
MSC 7804, Bethesda, MD 20892, 301–806–
2515, chatterm@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Cancer,
Cardiovascular and Sleep Epidemiology
Panel B Study Section.
Date: October 19–20, 2015.
Time: 8:30 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Melrose Hotel, 2430 Pennsylvania
Avenue NW., Washington, DC 20037.
Contact Person: Ellen K. Schwartz, EDD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3144,
MSC 7770, Bethesda, MD 20892, 301–828–
6146, schwarel@mail.nih.gov.
Name of Committee: Infectious Diseases
and Microbiology Integrated Review Group;
Virology—A Study Section.
Date: October 26–27, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Renaissance Washington DC,
Dupont Circle, 1143 New Hampshire Avenue
NW., Washington, DC 20037.
Contact Person: Kenneth M. Izumi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3204,
MSC 7808, Bethesda, MD 20892, 301–496–
6980, izumikm@csr.nih.gov.
Name of Committee: Immunology
Integrated Review Group; Innate Immunity
and Inflammation Study Section.
Date: October 29–30, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites Alexandria-Old
Town, 1900 Diagonal Road, Alexandria, VA
22314.
Contact Person: Tina McIntyre, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4202,
MSC 7812, Bethesda, MD 20892, 301–594–
6375, mcintyrt@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Special
Topic: Development Functions and Immune
Mediated Diseases.
Date: October 30, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Capital View, 2850
South Potomac Avenue, Arlington, VA
22202.
Contact Person: Deborah Hodge, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4207
MSC 7812, Bethesda, MD 20892, (301) 435–
1238, hodged@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PARs:
Developing and Testing Interventions for
Health-Enhancing Physical Activity.
Date: October 30, 2015.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\25SEN1.SGM
25SEN1
]]>Agencies
[Federal Register Volume 80, Number 186 (Friday, September 25, 2015)]
[Notices]
[Pages 57832-57833]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-24331]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up Exclusive Evaluation Option License
Agreement: Development of Diagnostic Tests and Kits for Detection of
Pathological Angiogenesis in Cancer
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR
part 404, that the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant of a Start-Up Exclusive
Evaluation Option License Agreement to Angio360 Diagnostics, LLC, a
company having a place of business in Wauwatosa, Wisconsin, to practice
the inventions embodied in U.S. Provisional Patent Application No. 60/
858,068, entitled ``Differential Gene Expression in Physiological and
Pathological Angiogenesis,'' filed November 9, 2006 (HHS Ref. No.: E-
285-2006/0-US-01); US Provisional Patent Application No. 60/879,457,
entitled ``Organ And Tumor Associated Endothelial Markers,'' filed
January 8, 2007 (HHS Ref. No. E-285-2006/1-US-01); PCT Application No.
PCT/US2007/072395, entitled ``Differential Gene Expression in
Physiological and Pathological Angiogenesis,'' filed June 8, 2007 (HHS
Ref. No. E-285-2006/2-PCT-01); U.S. Patent Application No. 12/514,297,
entitled ``Differential Gene Expression in Physiological and
Pathological Angiogenesis,'' filed May 8, 2009 (HHS Ref No. E-285-2006/
2-US-02); Australian Patent No. 2007-317753, entitled ``Differential
Gene Expression in Physiological and Pathological Angiogenesis,'' filed
June 28, 2007 (HHS Ref No. E-285-2006/2-AU-03); Canadian Patent
Application No. 2,669,260, entitled ``Differential Gene Expression in
Physiological and Pathological Angiogenesis,'' filed June 28, 2007 (HHS
Ref. No. E-285-2006/2-CA-04); U.S. Patent No.: 8,440,411, entitled
``Differential Gene Expression in Physiological and Pathological
Angiogenesis,'' filed March 21, 2011 (HHS Ref. No. E-285-2006/2-US-05);
U.S. Patent Application No. 13/052,878, entitled ``Differential Gene
Expression in Physiological and Pathological Angiogenesis,'' filed
April 16, 2013 (HHS Ref. No.: E-285-2006/2-US-06); and Australian
Application Patent No.: 2014-200453, entitled ``Differential Gene
Expression in Physiological and Pathological Angiogenesis,'' filed
January 28, 2014 (HHS Ref No. E-285-2006/2-AU-07). The patent rights in
these inventions have been assigned to the Government of the United
States of America. The territory of the prospective Start-Up Exclusive
Evaluation Option License Agreement may be worldwide, and the field of
use may be limited to ``Development of diagnostic tests and kits to
determine or monitor pathological angiogenesis related to cancer in
animals or humans.''
[[Page 57833]]
Upon the expiration or termination of the Start-up Exclusive
Evaluation Option License Agreement, Angio360 Diagnostics, LLC will
have the exclusive right to execute a Start-Up Exclusive Patent License
Agreement which will supersede and replace the Start-up Exclusive
Evaluation Option License Agreement, with no greater field of use and
territory than granted in the Start-up Exclusive Evaluation Option
License Agreement.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
October 13, 2015 will be considered.
ADDRESSES: Requests for copies of the patent application(s), inquiries,
comments, and other materials relating to the contemplated Start-Up
Exclusive Evaluation Option License Agreement should be directed to:
Rose M. Freel, Licensing and Patenting Manager, Office of Technology
Transfer, National Institutes of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852-3804; Telephone: (301) 402-9521;
Facsimile: (301) 402-0220; Email: rose.freel@nih.gov. A signed
confidentiality nondisclosure agreement will be required to receive
copies of any patent applications that have not been published or
issued by the United States Patent and Trademark Office or the World
Intellectual Property Organization.
SUPPLEMENTARY INFORMATION: This technology describes a method of
detecting pathological angiogenesis (formation of new blood vessels)
using the expression levels of certain proteins for the diagnosis of
cancer or monitoring response to cancer treatment.
The prospective Start-Up Exclusive Evaluation Option License
Agreement is being considered under the small business initiative
launched on October 1, 2011 and will comply with the terms and
conditions of 35 U.S.C. 209 and 37 CFR part 404. The prospective Start-
Up Exclusive Evaluation Option License Agreement and a subsequent
Start-Up Exclusive Patent License Agreement may be granted unless the
NIH receives written evidence and argument, within fifteen (15) days
from the date of this published notice, that establishes that the grant
of the contemplated Start-Up Exclusive Evaluation Option License
Agreement would not be consistent with the requirements of 35 U.S.C.
209 and 37 CFR part 404.
Complete applications for a license in the prospective field of use
that are filed in response to this notice will be treated as objections
to the grant of the contemplated Start-Up Exclusive Evaluation Option
License Agreement. Comments and objections submitted to this notice
will not be made available for public inspection and, to the extent
permitted by law, will not be released under the Freedom of Information
Act, 5 U.S.C. 552.
Dated: September 21, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of
Health.
[FR Doc. 2015-24331 Filed 9-24-15; 8:45 am]
BILLING CODE 4140-01-P
